It was announced late last week that the FTC provided the antitrust approval. The merger was on a list of proposed transactions for the FTC to oversee. The federal agency offered a very fast approval since the merging firms had either very few or no overlaps whatsoever.
Tesla CEO Elon Musk presented the proposal earlier this summer. The offer was worth $2.6 billion. After some intensive lobbying and combating against public opinion, the merger was completed on Aug. 1.
Officials still had to seek approval from the government. The initiative is part of Tesla’s efforts to enhance economies of scale when it comes to battery production, electrical energy management systems and marketing.
Although Tesla plans to take advantage of SolarCity’s technology, it is SolarCity that benefits more. The solar firm, which has been struggling over the last 12 months, has found it very difficult to compete because of the growing competition. Other solar firms have been offering consumers with low-cost solar energy and installations. Moreover, SolarCity has been hurt by state governments veering away from subsidies that intended to ramp up rooftop solar installations.
Full Content: Petro Global News
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas